Replies to post #125818 on Biotech Values

[iwfal]

MNTA -

The Court’s separate ruling today on the Markman hearing is somewhat of a concern to MNTA investors.

Has anyone on the board done an analysis of Momenta's strategy with regard to claim construction and how it bears on their over-all Copaxone patent strategy? It could be vital - or it could be only a minor issue.

[jb_118]

MNTA

I still expect Teva to settle the Copaxone patent case when the FDA approves NVS/MNTA’s ANDA, if the patent case has not run its course by then.

IF TEVA isn't in a dealing mood, how to you model the chances of Sandoz launching at-rsik?